Trial Profile
A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 11 Apr 2019
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Ruxotemitide (Primary)
- Indications Advanced breast cancer; Cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Sarcoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Lytix Biopharma
- 03 Apr 2019 Results (n=27) assessing safety and efficacy of LTX-315 in patients with advanced melanoma presented at the 110th Annual Meeting of the American Association for Cancer Research
- 03 Apr 2019 Results (n=27) from advanced sarcoma cohort were presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 21 Nov 2018 Results presented in the Lytix Biopharma media release.